GNPX - Genprex's Reqorsa combo shows encouraging activity in lung cancer shares up 3%

Genprex (GNPX) presents positive preclinical data for the combination of TUSC2 immunogene therapy (Reqorsa) in combination with chemotherapy and immunotherapies for the treatment of non-small cell lung cancer ((NSCLC)). These data were presented at the AACR Meeting 2021. The first presentation showed that, the triple combination of chemotherapy, immunotherapy and Reqorsa demonstrated strong antitumor efficacy and induced robust antitumor immunity in KRAS-LKB1 ((KL))-mutant NSCLC in clinically relevant humanized mice models. When Reqorsa was added to the chemotherapy and immune checkpoint blockade combination, metastases regression was significantly greater than either Reqorsa, Reqorsa and pembrolizumab, or chemotherapy and pembrolizumab treatments. The second poster demonstrated that, Reqorsa in combination with targeted therapy osimertinib (Tagrisso) demonstrated synergistic antitumor efficacy in EGFR mutant osimertinib resistant NSCLC tumors in H1975-OsiR isogenic tumors. Researchers also found that the upregulation of PDK1 was associated with osimertinib resistance. The combinations showed a robust antitumor effect compared with single agent treatment

For further details see:

Genprex's Reqorsa combo shows encouraging activity in lung cancer, shares up 3%